Johnson & Johnson lowers 2026 profit forecast

JNJ•2026-07-29

2026 profit forecast cut after acquisition and partnership

July 29 (Reuters) - Johnson & Johnson JNJ.N cut 2026 profit forecast on Wednesday, citing the combined financial impact of its newly completed acquisition of Firefly Bio and a strategic partnership with Sail Biomedicines.

The healthcare giant expects full-year adjusted earnings per share of $10.96 to $11.11, compared with its previous forecast of $11.60 to $11.75.

Johnson & Johnson lowers 2026 profit forecast

2026 profit forecast cut after acquisition and partnership

Related News

European Commission Authorizes Pfizer And Biontech Xfg-Adapted Covid-19 Vaccine In The European Union

Claritev sees No Surprises Act IDR dispute initiations top 5.1 million through January 2026

Hii Is Awarded Contracts For Construction Of Block Vi Virginia-Class And Build Ii Columbia-Class Submarines

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. To Advance Next-Generation Oncology Innovation

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)